Antimicrobial Resistance Among GLASS Pathogens In Morocco: An Epidemiological Scoping Review

Chakib Nejari

Mohammed VI University of Health Sciences (UM6SS)

Youness El Achhab (✉ youness_elachhab@yahoo.fr)

Clinical Research and Community Health

Amina Benaouda

Cheikh Zayed International University Hospital

Chakib Abdelfattah

University Hassan II

Research Article

Keywords: Antimicrobial resistance, Bacteria, Morocco, Global antimicrobial resistance surveillance system, scoping review

Posted Date: February 14th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1265452/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Monitoring of antimicrobial resistance (AMR) is of great importance due to the frequency of strains becoming increasingly resistant to antibiotics. This review, using a public health focused approach, aimed to understand and describe the current status of AMR in Morocco in relation to WHO priority pathogens and treatment guidelines.

Methods: PubMed, ScienceDirect and Google Scholar Databases and grey literature were searched published articles on antimicrobial drug resistance data for GLASS priority pathogens isolated from Morocco between January 2011 and December 2021. Articles were screened using strict inclusion/exclusion criteria. AMR data was extracted with medians and IQR of resistance rates.

Results: Forty-nine articles were included in the final analysis. The most reported bacterium was *Escherichia coli* with median resistance rates of 90.9%, 64.0%, 56.0%, 47.8%, 34.4%, 34.0%, and 23.0% for amoxicillin, amoxicillin-clavulanic acid, co-trimoxazole, nalidixic acid, ceftriaxone, fluoroquinolones, and gentamicin, respectively. Colistin had the lowest median resistance with 0.1% (range 0.0-11.9%).

Conclusions: Whilst resistance rates are high for most of GLASS pathogens, there were deficient data to draw vigorous conclusions about the current status AMR in Morocco. The recently join to the GLASS system surveillance will begin to address this data gap.

Background

Antimicrobial resistance (AMR) is increasingly recognized as a global public health issue by leading to a high rate of morbidity and mortality [1, 2]. By 2050, the global mortality attributed to AMR could reach 10 million per year; this will pose a significant threat to the global economy if measures are not taken to curb the problem [3]. The antimicrobials misuse and abuse in veterinary and human medicine have accelerated the growing worldwide phenomenon of AMR [4–6]. Moreover, the use of antimicrobials in the food chain endanger sustainable food production and food security [7].

In October 2015, the World Health Organization (WHO) launched the Global Antimicrobial Resistance Surveillance System (GLASS), as a necessary contribution to the global action plan against AMR. Morocco has joined GLASS system by the end of 2018 [8]. Recent AMR data collected from two million patients over 66 countries show high rates of resistance among antimicrobials frequently used to treat common bacterial infections [9]. The main AMR profiles were defined as those identified by WHO as “priority pathogens” for the public health significance. There were eight organisms: *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Salmonella* spp., *Shigella* spp., and *Neisseria gonorrhoeae* [9] (appendix 1). Pathogen-antimicrobial combinations under GLASS surveillance include penicillins, third- and fourth-generation cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, tetracyclines, polymyxins, macrolides, and co-trimoxazole.

In Morocco, recently, the Ministry of Health creates the national coordination unit and the technical committee for the surveillance of AMR. However, earliest studies highlighted the resistance seriousness of microorganisms to antibiotics [10–12]. To date, however, these data have not been brought together to provide a country level perspective. This review aims to describe the recent published AMR data from Morocco and gives a summary of key AMR patterns in the country by focusing on the organisms identified by WHO-GLASS.

Methods

Sources of information and search strategies

PubMed, SciencDirect, and the Google Scholar were searched for papers from January 1, 2011 to December 20, 2021. Search strategy in PubMed database was performed on MeSH terms (see appendix 2.). In addition, we searched related reviews and references for relevant studies. The design of this proposed scoping review methodology was informed by Arksey and O'Malley's framework [13] and The Joanna Briggs Institute Reviewers' Guidance [14]. The selection of articles for review was done by three-stage method whereby the title alone was examined, followed by looking at abstract, and then examining the whole article (Figure 1).

Eligibility: Inclusion and exclusion criteria

All original articles written in English or French languages reporting the prevalence of antibiotic resistance in bacteria strains isolated from humans by standard laboratory tests were included.

The inclusion criteria include:

- Reports on AMR in humans from Morocco,
- Information about antibiotic resistance of at least one bacterium,
- The denominator as total isolates clearly described for population-based studies,
- Correspondence and abstracts published with sufficient information on methodology and results.

The exclusion criteria include reports published before 2011, studies only focused on HIV or tuberculosis without AMR information, reviews, and studies without information on total studied isolates.

Article quality assessment

The quality of each article was assessed using the modified critical appraisal checklist recommended by the Joanna Briggs Institute [15] (appendix 3). Quality assessment of studies was performed by two reviewers independently. Disagreements were resolved by a consensus-based discussion. Nine items were used as quality criteria for assessing the design, details of sample collection, processing and reporting on AMR methodologies.

Data extraction and analysis

Data extraction was done using a predesigned and pretested database, developed for the purpose of this review using Microsoft Excel 2016 spreadsheet (appendix 4). Data extracted were name of first author, publication date, sample size, time and location of study, laboratory methodological information (pathogen identification and antimicrobial susceptibility testing methodology) and antibacterial resistance data.

Intermediate susceptibility, where reported, was considered as resistant. Where susceptibility rates were reported, without resistance rates, the resistance rates were calculated as the inverse of the susceptibility rates. Data were independently collected by two authors.

Results

Data and study characteristics

In total, 14 662 articles were collected from the initial literature search, and from them only 61 were eligible for data abstraction (Figure 1). However, after full assessment, 12 articles were excluded due to data overlapping or duplication [16–18] and for difficulties to abstract data [19–27]. Finally, 49 papers fulfilling the inclusion criteria were included in the final analysis [28–76]. Characteristics of included studies are summarized in Table 1.

Of the 49 included studies, 13 reported isolates from children only, while 14 not reported age of patients. The majority of included studies (38) used the disk diffusion method as the antibiotic-susceptibility test. Some studies used agar dilution and broth dilution combined, referred to as MIC testing for the analysis. The most commonly reported organism was *E. coli*, with AMR data reported by 23 papers. In contrast, AMR data was reported by one paper for *Shigella* spp. [38], one paper for *N. gonorrhoea* [50] and two papers for *Salmonella* spp. [38, 43] (Table 1).

Microbial resistance patterns

Escherichia coli

The most commonly reported bacterium was *E.coli*. it was reported in 22 studies [28, 30–33, 35, 36, 38, 45, 47, 49, 54–56, 58, 62, 64–67, 69, 75]. Median resistances were calculated as 64.0% (n = 21, IQR 47.1-71.4), 90.9% (n = 13, IQR 78.8-95.3), 34.0% (n = 23, IQR 26.3-71.7), 56.0% (n = 19, IQR 32.7-70.3), 23.0% (n = 23, IQR 15.8-53.7), 3.4% (n = 22, IQR 2.1-11.0), 47.8% (n = 9, IQR 34.9-72.5), and 15.1% (n=11, IQR 6.6-23.9) for amoxicillin-clavulanic acid, amoxicillin, fluoroquinolones, co-trimoxazole, gentamicin, amikacin, nalidixic acid and ceftazidime, respectively (Table 2). For 3GC, median resistances were calculated as 28.7% (n = 8, IQR 15.7-49.3), 34.4% (n = 14, IQR 13.0-71.9), and 31.8% (n = 12, IQR 18.0-84.0) for ceftriaxone, cefotaxime and ceftazidime, respectively. Colistin resistance was reported as 0.1% (n=7, IQR 0.0-11.9). Carbapenem resistance was studied in 21 papers and calculated as 3.0% (IQR 0.0-11.8).

Klebsiella pneumonia

AMR data on *K. pneumonia* was reported in 16 studies [30–32, 34, 35, 40, 45, 47, 49, 56, 58, 63–67] (Table 3). Median resistances were calculated as 63.0% (n = 15, IQR 59.5-80.9), 100.0% (n = 7), 42.9% (n = 15, IQR 29.8-73.9), 50.9% (n = 12, IQR 45.6-80.8), 50.0% (n = 15, IQR 36.8-86.7), 4.9% (n = 14, IQR 1.4-25.0), 42.9% (n = 5, IQR 36.4-48.2) for amoxicillin-clavulanic acid, amoxicillin, fluoroquinolones, co-trimoxazole, gentamicin, amikacin and nalidixic acid respectively. Carbapenem resistance was reported by 15 papers with a median rate of 12.4% (IQR 6.7-35.0). For 3GC, median resistances were calculated as 58.6% (n = 6, IQR 52.5-77.5), 63.7% (n = 9, IQR 40.4-86.7), 61.9% (n = 10, IQR 42.1-85.9) for ceftriaxone, cefotaxime and ceftazidime respectively. Colistin resistance was reported as 17.0% (IQR 8.3-24.0) in four studies [35, 49, 63, 64].

Acinetobacter baumannii

Thirteen papers reported data for *A. baumannii* [29, 48, 49, 51, 55, 56, 58–61, 63, 72, 74] (Table 4). Except for El Mekes *et al.* study [55], all papers reported imipenem resistance with a median 74.5% (IQR 65.8-79.7). Three studies reported resistance rates of 90.9%, 64.0% and 65.6% to tetracyclines [51, 72, 74]. Higher resistance to ticarcillin and piperacillin was reported in nine studies (92.6%, IQR 89.3-100.0). AMR resistance to 3GC, especially represented by ceftazidime, was reported as a median of 85.5% (n=10, IQR 82.9-92.6). Gentamicin and amikacin resistance was reported with rates of 87.0% (n =9, IQR 79.8-94.0) and 52.3% (n=11, IQR 47.5-62.8) respectively. Colistin resistance was reported in eight studies as 0.0%, (IQR 0.0-1.2). Cefepime (4CG) resistance was reported by four studies as 87.6% (IQR 86.2-91.2) [48, 61, 72, 74].

Salmonella spp.

Two papers reported resistance data for *Salmonella* spp. in humans [38, 43]. In the study of Benmessaoud *et al.* [38], resistance to 3CG, 4CG, imipenem and amikacin was not detected. Resistance to tetracyclines, fluoroquinolones (ciprofloxacin and levofloxacin) and co-trimoxazole was reported as 60.0%, 20.0% and 40.0%, respectively. The results reported by Ed-Dra *et al.*, [43] showed that 84.6% (22/26) of the *Salmonella Infantis* strains were susceptible to all of the 14 antibiotics tested. Three strains were resistant to tetracycline, two strains had low-level β -lactam resistance and one strain was resistant to streptomycin and sulfonamide.

Shigella spp.

One study reported AMR data for *Shigella* spp. among nine isolates including six *S. sonnei* [38]. No resistance found to 3CG, fluoroquinolones and imipenem. Resistance higher than 50% was reported to tetracycline (55.5%) and co-trimoxazole (66.7% for all strains and 83.3% for *S. sonnei*).

Neisseria gonorrhoeae

One study reported AMR data for *N. gonorrhoeae* among 72 isolates recruited from 171 men [50]. Resistance to ciprofloxacin was identified in 86.8% of *N. gonorrhoeae* strains, 16.2% were resistant to penicillin and 92.6% were resistant to tetracycline. All the isolates were 100% susceptible to ceftriaxone, cefixime and spectinomycin. In this study, evolution of resistance in *N. gonorrhoeae* strains isolated in 2001 and 2009 was reported. The AMR study in 2009 demonstrated an increasing trend of resistance in *N. gonorrhoeae* to tetracycline (from 59.7% in 2001 to 92.6% in 2009) and to ciprofloxacin (from 2.6% in 2001 to 86.7% in 2009).

Staphylococcus aureus

Six papers reported *S. aureus* among human populations [42, 44, 53, 59, 70, 76]. MRSA rates ranged from 1.6% to 31.1%. Diawara *et al.* [42] reported that only one strain per 62 isolates (1.6%) expressed an inhibition around ceftiofur and moxalactam disks, which was confirmed as MRSA. In the study of Ed-dyb *et al.* [44], 49 strains of *S. aureus* were isolated and the prevalence of MRSA was 4% (2/49) of *S. aureus* isolates. The rate of MRSA in hemodialyzed patients was 2.1% (1/47) in the study of Elazhari *et al.* [53]. In the study of Frikh *et al.* [59], *S. aureus* was the second most prevalent isolate with a rate of 14.9%, of which 31.1% were MRSA. The prevalence of MRSA strains was 12.5% (3/24) in the study of Souly *et al.* [70]. The overall prevalence of MRSA in the study of Zrouil *et al.* [76] was 18.4%.

Streptococcus pneumoniae

AMR data for *St. pneumoniae* was reported by seven studies [37, 39, 41, 52, 56, 71, 73] and not exceed 50.0% as a median (resistance to tetracycline with IQR 30.5-83.7) (Table 5). Resistance to penicillin G, co-trimoxazole, erythromycin was reported as 36.7% (n = 6, IQR 10.0-86.1), 33.3% (n = 5, IQR 19.8-46.1) and 21.0% (n = 5, IQR 15.5-81.0), respectively. Ceftriaxone resistance was reported by four studies as a median of 5.8% (IQR 0.3-30.4).

In a case study [68], Néhémie *et al.* reported characteristics of a 35-year-old female patient. An ovarian transposition was performed in the Ibn Rochd University Hospital Centre of Casablanca. Antibiotic susceptibility tests were performed by disc diffusion and E-test method. The strain isolated was resistant to oxacillin, erythromycin, ampicillin, clindamycin, penicillin G and co-trimoxazole. It was only susceptible to vancomycin, levofloxacin and chloramphenicol and intermediate to ceftriaxone.

Discussion

Over the last decade in Morocco, there has been no comprehensive review dealing with the AMR prevalence using the global antimicrobial resistance surveillance system (GLASS). This attempt seeks, hopefully, to fill the gap and clarify the AMR status in the country's regions. The AMR data depicts high heterogeneity due to unstandardized laboratory methods, clinical conditions, and a few isolates. This makes drawing firm conclusions highly challenging. However, resistance rates to several key clinically important antibiotics were found to be alarmingly high.

To this end, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards were recommended over the Clinical and Laboratory Standards Institute (CLSI) guidelines. Moreover, improved access to quality assurance is needed to enhance the current WHO initiative, and scale up the global antimicrobial surveillance system (GLASS) based on country-specific priority pathogens [9].

In a recent systematic review conducted in the MENA region [77], it was shown that the lack of consistency and harmonization in the regional surveillance system is not a prerogative of the Middle East, as is the case in developed countries.

The most frequently GLASS pathogens belong to the Enterobacteriaceae family (*E. coli* and *K. pneumoniae*), *A. baumannii*, and *S. aureus*. They have been described in most of selected papers. Other systematic reviews, conducted on AMR in the Middle East [77] and Africa [78], have reported the same results. Concerning *Shigella* spp. and *N. gonorrhoeae*, each has been cited by only one paper. *Shigella* spp. was the second leading cause of diarrheal mortality, which accounts for 13.2% of diarrheal deaths globally [79] whereas, *N. gonorrhoeae* causes high levels of morbidity in LMICs, and shows the rapid development of AMR [8, 9].

Enterobacterales are a large order of different types of bacteria that commonly cause infections both in healthcare settings and communities. This family represented especially by *E. coli* and *K. pneumoniae* can produce extended-spectrum beta-lactamases (ESBLs) Enzymes. The latter break down some commonly used antibiotics such as penicillins and cephalosporins, which render them inefficient [80]. The WHO has recently published a global priority list of antibiotic-resistant bacteria, which includes ESBL-producing Enterobacteriaceae and carbapenemase-producing Enterobacteriaceae [8, 9]. Carbapenem resistance may be caused by different mechanisms, one of them being inducible overexpression of chromosomal cephalosporinases combined with porin loss [81, 82]. Enterobacteriaceae with ESBL/carbapenemase genes are bestowed with highly multi-drug resistance among humans, animals, and food chains [83]. Moreover, careless use of these antibiotic classes would co-select for resistance genotypes against the others [83].

The proportion of AMR driven from this review is alarming. The highest proportion of studies on both *E. coli* and *K. pneumoniae* were related to urinary tract infections. Such cases require more complex treatments [9]. Such infections might require hospitalization and intravenous injection of carbapenem antibiotics. In this review, the carbapenem-resistance proportion among GLASS Enterobacteriaceae appears like other reports from Africa [78] and the Middle East [77], but higher than those described in most European countries [84]. In this context, the prevalence of carbapenemase-producing *K. pneumoniae* and *E. coli*, per 10 000 hospital admissions, presents an average of 1.3 (6.0 in Italy, 0.02 in Norway). The incidence per 100 000 hospital patient-days ranged from

17.3 in Greece to 0.09 in Lithuania, with a mean of 2.5 across all the countries. In China, the overall carbapenem-resistant *Enterobacteriaceae* infection incidence per 10 000 discharges was 4.0 and varies significantly by region [85]. However, no carbapenem-resistant *Enterobacteriaceae* was found in a recent systematic review from Cambodia [86]. Carbapenemases have a global distribution, but substantial variability exists at the regional and continental levels.

In the past decade, numerous review papers have highlighted the rising problem of colistin resistance worldwide, especially with *E. coli*, *K. pneumonia*, and *A. Baumannii* in the human community [77, 78, 87–90]. Current and emerging colistin resistance may be explained by its high usage in the animal field, and this not only as an infection-healing drug but also as a growth promoter and protective agent [91]. Following this study, several reviews have also reported high 3GC, co-trimoxazole, fluoroquinolones, and gentamicin resistance among *E. coli* and *K. pneumoniae* isolates [77, 78, 90].

In the current review, the pathogens isolated from humans such as *Salmonella* spp., *Shigella* spp., and *N. gonorrhoeae* are understudied in the Morocco context. However, AMR in *Salmonella* spp. from foods and environmental sources was mentioned by several studies [92, 93]. Such finding is also revealed by other systematic reviews in other countries [77, 78]. On the other hand, *N. gonorrhoeae* is known for its high resistance to ciprofloxacin [94, 95]. Of note, ciprofloxacin, which is used to treat gonococcal infections, done by, was replaced by ceftriaxone in the Moroccan context [50]. This decision was sustained by previous studies [96] stating that penicillin, tetracycline, and ciprofloxacin should not be used for *N. gonorrhoeae* management in Morocco. For *Salmonella* spp., the prevalence of fluoroquinolone resistance has exceeded 30% in many areas of the Arab World [97]. This remains significantly high when compared with the Moroccan context, where it does not surpass 20%.

The epidemiology of *S. aureus*, especially that of MRSA, has shown a rapid evolution over the last years. Global surveillance has emphasized that MRSA represents a problem in all countries showing an increase in the mortality and need to use last-resource antibiotics [8, 9, 98]. The proportion of MRSA (30%) reported in this review is still higher than that mentioned in the European countries (16.9%) [99], but lower than those reported in Asia (28 - 70%) [100], and Africa (53%) [101]. While the treatment options for MRSA are still limited, there are several new antimicrobials under development [102]. *S. pneumoniae* was reported as a major cause of community-acquired pneumonia, meningitis, sepsis, bacteremia, and otitis media [103, 104]. A decline in susceptibility of *S. pneumoniae* to commonly used beta-lactams, fluoroquinolones, and macrolides was mentioned by several studies [103, 105, 106].

Although the findings of this study may seem useful, some limitations must be considered when the interpretation of the results is required. The strict focus on GLASS bacteria might have led to oversight of important pathogens like *Helicobacter pylori* [107, 108], and *Pseudomonas aeruginosa* [109, 110], which are of significant public health concern in AMR. The Validity and generalizability of the findings to the entire country's regions might be affected by the clinical-based, cross-sectional study design of the published papers, mainly collected from Casablanca and Marrakech cities. Besides, there is high variability among the criteria relevant to methodology and interpretation. This is consonant with the data depicted elsewhere in recent similar reviews [77, 78, 86, 90]. There are some calls to adopt standardized AMR data presented in published papers, wishing to make the findings interpretable and comparable from the perspective of scarce homogeneity [111]. Despite these limitations, the high proportion of AMR detected in this review has a certain degree of validity.

Conclusions

In summary, this review highlights that data on AMR in Morocco are limited but improving. Overall, there were significant similarities in AMR tendency in comparison with other countries worldwide. The recent joining of Morocco to the GLASS system will improve the accuracy, quality, and comparability of data collected on AMR.

Abbreviations

ABRI: *Acinetobacter baumannii* resistant to imipenem; ADM: agar dilution method; AK: Amikacin; AMR: Antimicrobial resistance; AMX-C: Amoxicillin-clavulanic acid; AMX: amoxicillin; BMD: broth microdilution C3G: Third-generation cephalosporins; Carb: Carbapenems; CAZ: Ceftazidime; CFX: Cefoxitin; CIP: Ciprofloxacin; CLSI: Clinical and Laboratory Standards Institute; CRO: Ceftriaxone; Cs: Colistin; CTX: Cefotaxime; DDM: Disk Diffusion Method; ESBL: Extended Spectrum Beta Lactamase; E Test: Epsilometer test; *E. coli*: *Escherichia coli*; EUCAST: European Committee on Antimicrobial Susceptibility Testing; GLASS: Global Antimicrobial Resistance Surveillance System; GM: Gentamicin; Fluorq: Fluoroquinolones; HIV: Human Immunodeficiency Virus; MENA: Middle East and North Africa; IQR: Interquartile Range; MIC: Minimum Inhibitory Concentration; NA: Nalidixic acid; MRSA: Methicillin-Resistant *Staphylococcus aureus*; SXT: Trimethoprim-sulfamethoxazole; UH: University hospital; WHO: World Health Organization

Declarations

Ethics approval and consent to participate

Not applicable in virtue of the study design (systematic literature review).

Consent for publication

Not applicable in virtue of the study design (systematic literature review).

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was sponsored by Sothema, which included compensation for services related to preparing this manuscript.

Authors' contributions

Study concept and design: CN and YE. Acquisition of data: CN and YE, Analysis and interpretation of data: CN, YE, AB and CA. Drafting of the manuscript: CN and YE. Critical revision of the manuscript for important intellectual content: All authors. All the authors read and approved the final version of the manuscript.

References

1. Limmathurotsakul D, Dunachie S, Fukuda K, Feasey NA, Okeke IN, Holmes AH, et al. Improving the estimation of the global burden of antimicrobial resistant infections. *The Lancet Infectious Diseases*. 2019;19.
2. Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: A global emerging threat to public health systems. *Critical Reviews in Food Science and Nutrition*. 2017;57:2857–76.
3. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance. 2016.
4. Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: A global emerging threat to public health systems. *Critical Reviews in Food Science and Nutrition*. 2017;57.
5. Pieri A, Aschbacher R, Fasani G, Mariella J, Brusetti L, Pagani E, et al. Country Income Is Only One of the Tiles: The Global Journey of Antimicrobial Resistance among Humans, Animals, and Environment. *Antibiotics*. 2020;9.
6. Bourély C, Coeffic T, Caillon J, Thibaut S, Cazeau G, Jouy E, et al. Trends in antimicrobial resistance among *Escherichia coli* from defined infections in humans and animals. *Journal of Antimicrobial Chemotherapy*. 2020;75.
7. George A. Antimicrobial Resistance (AMR) in the Food Chain: Trade, One Health and Codex. *Tropical Medicine and Infectious Disease*. 2019;4.
8. WHO. Global Antimicrobial Resistance Surveillance System (GLASS) Report. Early implementation 2017-18. 2018.
9. WHO. Global antimicrobial resistance and use surveillance system (GLASS) report. Early implementation 2020. 2020.
10. Filali E, Bell J, Elhouadfi M, Huggins M, Cook J. Antibiotic resistance of *Escherichia coli* strains isolated from chickens with colisepticaemia in Morocco. *Comparative Immunology, Microbiology and Infectious Diseases*. 1988;11.
11. Carlos F. Amábile-Cuevas. Antimicrobial Resistance in Developing Countries. New York, NY: Springer New York; 2010.
12. Ousaid A, Akrim J, Khayati Y. Overuse of antibiotics as a key driver to antibiotic resistance in Morocco: A short review with potential solutions. *The International Arabic Journal of Antimicrobial Agents*. 2020;10.
13. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology*. 2005;8.
14. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. *International Journal of Evidence-Based Healthcare*. 2015;13.
15. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *International Journal of Evidence-Based Healthcare*. 2015;13.
16. Benmessaoud R, Jroundi I, Moraleda C, Alvarez-Martínez MJ, Pons MJ, Chaacho S, et al. Aetiology, Epidemiology and clinical characteristics of acute moderate-to-severe diarrhoea in children under 5 years of age hospitalized in a referral paediatric hospital in Rabat, Morocco. *Journal of Medical Microbiology*. 2015;64:84–92.
17. el Bouamri MC, Arsalane L, Kamouni Y, Berraha M, Zouhair S. Évolution récente du profil épidémiologique des entérobactéries uropathogènes productrices de β -lactamases à spectre élargi à Marrakech, Maroc. *Progres en Urologie*. 2014;24:451–5.
18. el bouamri MC, Arsalane L, Kamouni Y, Yahyaoui H, Bennouar N, Berraha M, et al. Profil actuel de résistance aux antibiotiques des souches d'*Escherichia coli* uropathogènes et conséquences thérapeutiques. *Progres en Urologie*. 2014;24:1058–62.
19. Barguigua A, el Otmani F, Talmi M, Zerouali K, Timinouni M. Emergence of carbapenem-resistant Enterobacteriaceae isolates in the Moroccan community. *Diagnostic Microbiology and Infectious Disease*. 2012;73:290–1.
20. Barguigua A, Otmani F el, Talmi M, Bourjilat F, Haouzane F, Zerouali K, et al. Characterization of extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates from the community in Morocco. *Journal of Medical Microbiology*. 2011;60:1344–52.
21. Bourjilat F, Bouchrif B, Dersi N, David J, Gros Claude P, Amarouch H, et al. Emergence of extended-spectrum beta-lactamase-producing *Escherichia coli* in community-acquired urinary infections in Casablanca, Morocco. 2011.

22. el Hamzaoui N, Berguigua A, Nayme K, Mohamed S, Timinouni M, Louzi L. Prevalence of extended-spectrum beta-lactamases in uropathogenic Enterobacteriaceae isolated from a community setting, Meknes, Morocco. *Gene Reports*. 2020;19.
23. le Hello S, Harrois D, Bouchrif B, Sontag L, Elhani D, Guibert V, et al. Highly drug-resistant *Salmonella enterica* serotype Kentucky ST198-X1: A microbiological study. *The Lancet Infectious Diseases*. 2013;13:672–9.
24. Natoubi S, Barguigua A, Diawara I, Timinouni M, Rakib K, Amghar S, et al. Epidemiology of extended-spectrum β -lactamases and carbapenemases producing Enterobacteriaceae in Morocco. *Journal of Contemporary Clinical Practice*. 2020;6:75–85.
25. Nejmi H, Laghla B, Boutbaoucht M, Samkaoui MA. Évolution des résistances de l'*Escherichia coli* au cours des péritonites communautaires. *Médecine et Maladies Infectieuses*. 2011;41.
26. Ambroise J, Benaissa E, Irenge LMWB, Belouad EM, Bearzatto B, Durant J-F, et al. Genomic characterisation of extended-spectrum β -lactamase-producing multidrug-resistant *Escherichia coli* in Rabat, Morocco. *Journal of Global Antimicrobial Resistance*. 2021;26:335–41.
27. Farih S, Saddari A, Noussaiba B, Araab A, Yacoubi L, Benaissa E, et al. Health vigilance concerning female urinary tract infections: Epidemiological profile and antibiotic resistance. *E3S Web of Conferences*. 2021;319:01009.
28. Alem N, Frikh M, Srifi A, Maleb A, Chadli M, Sekhsokh Y, et al. Evaluation of antimicrobial susceptibility of *Escherichia coli* strains isolated in Rabat University Hospital (Morocco). *BMC Research Notes*. 2015;8.
29. Arhoune B, Oumokhtar B, Hmami F, Fakir S el, Moutaouakkil K, Chami F, et al. Intestinal carriage of antibiotic resistant *Acinetobacter baumannii* among newborns hospitalized in Moroccan neonatal intensive care unit. *PLoS ONE*. 2019;14.
30. Arhoune B, Oumokhtar B, Hmami F, Barguigua A, Timinouni M, el Fakir S, et al. Rectal carriage of extended-spectrum β -lactamase- and carbapenemase-producing Enterobacteriaceae among hospitalised neonates in a neonatal intensive care unit in Fez, Morocco. *Journal of Global Antimicrobial Resistance*. 2017;8:90–6.
31. Arhoune B, el Fakir S, Himri S, Moutaouakkil K, el Hassouni S, Benboubker M, et al. Intense intestinal carriage and subsequent acquisition of multidrug-resistant enterobacteria in neonatal intensive care unit in Morocco. *PLOS ONE*. 2021;16:e0251810.
32. Arsalane L, Zouhair S, Lahlou Amine I, Louzi L, Bouskraoui M. Infection urinaire du nourrisson (376 cas) dans un hôpital marocain (2009-2010) - fréquence étiologique et prévalence de la résistance. *Pathologie Biologie*. 2012;60.
33. Barguigua A, el Otmani F, Talmi M, Zerouali K, Timinouni M. Prevalence and types of extended spectrum β -lactamases among urinary *Escherichia coli* isolates in Moroccan community. *Microbial Pathogenesis*. 2013;61–62:16–22.
34. Barguigua A, Zerouali K, Katfy K, el Otmani F, Timinouni M, Elmdaghri N. Occurrence of OXA-48 and NDM-1 carbapenemase-producing *Klebsiella pneumoniae* in a Moroccan university hospital in Casablanca, Morocco. *Infection, Genetics and Evolution*. 2015;31:142–8.
35. Benaicha H, Barrijal S, Ezzakkioui F, Elmalki F. Prevalence of PMQR genes in *E. coli* and *Klebsiella* spp. isolated from North-West of Morocco. *Journal of Global Antimicrobial Resistance*. 2017;10:321–5.
36. Benaissa E, Elmrmar N, Belouad E, Mechali Y, Ghazouani M, Bsaibiss F, et al. Update on the resistance of *Escherichia coli* isolated from urine specimens in a Moroccan hospital: a review of a 7-year period. *GERMS*. 2021;11:189–98.
37. Benbachir M, Elmdaghri N, Belabbes H, Haddioui G, Benzaid H, Zaki B. Eleven-year surveillance of antibiotic resistance in *Streptococcus pneumoniae* in casablanca (Morocco). *Microbial Drug Resistance*. 2012;18:157–60.
38. Benmessaoud R, Nezha M, Moraleda C, Jroundi I, Tligui H, Seffar M, et al. Antimicrobial resistance levels among diarrhoeagenic micro-organisms recovered from children under-5 with acute moderate-to-severe diarrhoea in Rabat, Morocco. *Journal of Global Antimicrobial Resistance*. 2016;7:34–6.
39. Bouskraoui M, Soraa N, Zahlane K, Arsalane L, Doit C, Mariani P, et al. Étude du portage rhinopharyngé de *Streptococcus pneumoniae* et de sa sensibilité aux antibiotiques chez les enfants en bonne santé âgés de moins de 2 ans dans la région de Marrakech (Maroc). *Archives de Pédiatrie*. 2011;18:1265–70.
40. Chabah M, Chems M, Zerouali K, Alloula O, Lehlmi M, Habzi A, et al. Healthcare-associated infections due to carbapenemase-producing Enterobacteriaceae: Bacteriological profile and risk factors. *Medecine et Maladies Infectieuses*. 2016;46:157–62.
41. Diawara I, Zerouali K, Katfy K, Barguigua A, Belabbes H, Timinouni M, et al. Phenotypic and genotypic characterization of *Streptococcus pneumoniae* resistant to macrolide in Casablanca, Morocco. *Infection, Genetics and Evolution*. 2016;40:200–4.
42. Diawara I, Bekhti K, Elhabchi D, Saile R, Elmdaghri N, Timinouni M, et al. *Staphylococcus aureus* nasal carriage in hemodialysis centers of Fez, Morocco. *Iran J Microbiol*. 2014;6:175–83.
43. Ed-Dra A, Karraouan B, Allaoui A el, Khayatti M, Ossmani H el, Filali FR, et al. Antimicrobial resistance and genetic diversity of *Salmonella* *Infantis* isolated from foods and human samples in Morocco. *Journal of Global Antimicrobial Resistance*. 2018;14:297–301.

44. Ed-dyb S, Aboudourib M, Azzouzi F, Quidi W, Akhdari N, Amal S, et al. Prevalence of Community Acquired Methicillin Resistant *Staphylococcus aureus* Nasal Carriage among Children of Consultation: Experience of a Moroccan University Hospital. *Archives of Clinical Microbiology*. 2020;11.
45. el Bouamri MC, Arsalane L, el Kamouni Y, Zouhair S. Antimicrobial susceptibility of urinary *Klebsiella pneumoniae* and the emergence of carbapenem-resistant strains: A retrospective study from a university hospital in Morocco, North Africa. *African Journal of Urology*. 2015;21:36–40.
46. el Bouamri MC, Arsalane L, Zerouali K, Katfy K, el kamouni Y, Zouhair S. Molecular characterization of extended spectrum β -lactamase-producing *Escherichia coli* in a university hospital in Morocco, North Africa. *African Journal of Urology*. 2015;21:161–6.
47. Fassi F el, Malki F el, Benaicha H, Idaomar M, Barrijal S. High levels multi-resistance to antibiotics among extended-spectrum β -lactamases-producing *Enterobacteriaceae* from Northwest Morocco. 2014.
48. el Hafa H, Nayme K, el Hamzaoui N, Maroui I, Sbati M, Zerouali K, et al. Dissemination of carbapenem-resistant *Acinetobacter baumannii* strains carrying the blaGES, blaNDM and blaOXA23 in Morocco. *Germes*. 2019;9:133–41.
49. el Hamzaoui N, Barguigua A, Larouz S, Maouloua M. Epidemiology of burn wound bacterial infections at a Meknes hospital, Morocco. *New Microbes and New Infections*. 2020;38.
50. Hançali A, Ndowa F, Bellaji B, Bennani A, Kettani A, Charof R, et al. Antimicrobial resistance monitoring in *Neisseria gonorrhoeae* and strategic use of funds from the Global Fund to set up a systematic Moroccan gonococcal antimicrobial surveillance programme. *Sexually Transmitted Infections*. 2013;89 SUPPL. 4.
51. el Kettani A, Maaloum F, Diawara I, Katfy K, Harrar N, Zerouali K, et al. Prevalence of *Acinetobacter baumannii* bacteremia in intensive care units of Ibn Rochd University Hospital, Casablanca. *Iran J Microbiol*. 2017;9:318–23.
52. el Mdaghri N, Jilali N, Belabbes H, Jouhadi Z, Lahssoune M, Zaid S. Epidemiological profile of invasive bacterial diseases in children in Casablanca, Morocco: antimicrobial susceptibilities and serotype distribution. *Eastern Mediterranean Health Journal*. 2012;18.
53. Elazhari M, Elthmani F, Errouagui A, Elhabchi D, Saile R, Timinouni M. *Staphylococcus aureus* nasal carriage in centers of Casablanca (Morocco). *African Journal of Microbiology Research*. 2014;8:375–82.
54. el Hamzaoui N, Barguigua A, Timinouni M, Belhaj A. Epidemiology of Extended spectrum beta-lactamase Producing *Escherichia coli* isolated from hospital and community setting, Morocco. *International Multidisciplinary e-Journal*. 2015;4:206–17.
55. el mekes A, Zahlane K, Ait said L, Tadlaoui Ouafi A, Barakate M. The clinical and epidemiological risk factors of infections due to multi-drug resistant bacteria in an adult intensive care unit of University Hospital Center in Marrakesh-Morocco. *Journal of Infection and Public Health*. 2020;13:637–43.
56. Es-Said I, Elfazazi H, Zouhdi M. In vitro activity of imipenem combination with colistin or rifampicin against clinical isolates of *Acinetobacter baumannii* and his antimicrobial susceptibility profil. *International Journal of Innovation and Applied Studies*. 2014;8:1252–7.
57. Es-Said I, Mahdoufi R, Yagoubi M, Zouhdi M. Isolation and Antibiotic Susceptibility of Bacteria from Otitis Media Infections in Children in Rabat Morocco. *Journal of Biology, Agriculture and Healthcare*. 2014;4:153–9.
58. Essayagh T, Zohoun A, Essayagh M, Elameri A, Zouhdi M, Ihrai H, et al. Épidémiologie bactérienne à l'unité des brûlés de l'hôpital militaire d'instruction de rabat. *Annales de Biologie Clinique*. 2011;69:71–6.
59. Frikh M, Abdelhay L, Jalal K, Imad Y, Yassine B, Bouchra B, et al. Profile and Antibiotic Susceptibility of Bacteria Isolates in Burn Patients Hospitalized in a Moroccan Hospital: A Cross-sectional Study. *Wounds*. 2018;30:102–7.
60. Zohoun AGC, Mokit D, el Hamzaoui S. Résistance à l'imipénème par production de métallo- β -lactamases par *Acinetobacter baumannii* et *Pseudomonas aeruginosa* à l'Hôpital militaire d'instruction Mohammed V de Rabat. *Annales de Biologie Clinique*. 2013;71:27–30.
61. Kabbaj H, Seffar M, Belefquih B, Akka D, Handor N, Amor M, et al. Prevalence of Metallo- β -Lactamases Producing *Acinetobacter baumannii* in a Moroccan Hospital . *ISRN Infectious Diseases*. 2013;2013:1–3.
62. Kettani Halabi M, Lahlou FA, Diawara I, el Adouzi Y, Marnaoui R, Benmessaoud R, et al. Antibiotic Resistance Pattern of Extended Spectrum Beta Lactamase Producing *Escherichia coli* Isolated From Patients With Urinary Tract Infection in Morocco. *Frontiers in Cellular and Infection Microbiology*. 2021;11.
63. Lachhab Z, Frikh M, Maleb A, Kasouati J, Doghmi N, ben Lahlou Y, et al. Bacteraemia in Intensive Care Unit: Clinical, Bacteriological, and Prognostic Prospective Study. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2017;2017.
64. Loqman S, Soraa N, Diene SM, Rolain J-M. Dissemination of Carbapenemases (OXA-48, NDM and VIM) Producing *Enterobacteriaceae* Isolated from the Mohamed VI University Hospital in Marrakech, Morocco. *Antibiotics*. 2021;10:492.
65. Mouaffak Y, Boutbaoucht M, Soraa N, Chabaa L, Salama T, Oulad Saïad M, et al. Profil bactériologique des péritonites communautaires de l'enfant prises en charge au CHU de Marrakech. *Annales Francaises d'Anesthesie et de Reanimation*. 2013;32:60–2.

66. Moukrad N, Rhazi Filali F, Makoudy Y. Prévalence de la multi-résistance bactérienne aux antibiotiques des infections urinaires dans la ville de Meknès (Maroc) et son évolution dans le temps. ScienceLib Edition Mersenne. 2012;4.
67. Moutachakkir M, Chinbo M, Elkhoudri N, Soraa N. La résistance aux antibiotiques chez les entérobactéries uropathogènes en milieu pédiatrique au CHU de Marrakech. *Journal de Pédiatrie et de Puericulture*. 2015;28:16–22.
68. Néhémie N, Zerouali K, Diawara I, Katfy K, Maaloum F, Kabura S, et al. Surgical wound infection caused by a multi drug resistant *Streptococcus pneumoniae* Serotype 19A after a total coloproctectomy with ileostomy. *Pan African Medical Journal*. 2020;35.
69. Rafik A, Abouddihaj B, Asmaa D, Kaotar N, Mohammed T. Antibiotic resistance profiling of Uropathogenic Enterobacteriaceae, Casablanca, Morocco. *E3S Web of Conferences*. 2021;319:01002.
70. Souly K, Ait El kadi M, Lahmadi K, Biougnach H, Boughaidi A, Zouhdi M, et al. Epidemiology and prevention of *Staphylococcus aureus* nasal carriage in hemodialyzed patients. *Medecine et Maladies Infectieuses*. 2011;41:469–74.
71. Torumkune D, Hammami A, Mezghani Maalej S, ben Ayed N, Revathi G, Zerouali K, et al. Results from the survey of antibiotic resistance (SOAR) 2015-18 in Tunisia, Kenya and Morocco: Data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. *Journal of Antimicrobial Chemotherapy*. 2020;75.
72. Uwingabiye J, Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, et al. *Acinetobacter* infections prevalence and frequency of the antibiotics resistance: Comparative study of intensive care units versus other hospital units. *Pan African Medical Journal*. 2016;23.
73. Warda K, Oufdou K, Zahlane K, Bouskraoui M. Antibiotic resistance and serotype distribution of nasopharyngeal isolates of *Streptococcus pneumoniae* from children in Marrakech region (Morocco). *Journal of Infection and Public Health*. 2013;6:473–81.
74. Yacoubi L, Farih S, Benhamza N, Seddari A, maleb A. Health vigilance concerning *Acinetobacter baumannii* bacteremia at the mohammed VI university hospital of oujda (morocco): epidemiological profile and antibiotic resistance. *E3S Web of Conferences*. 2021;319:01003.
75. Zahir H, Draiss G, Rada N, Abourrahout A, Ait sab I, Sbihi M, et al. Écologie microbienne et sensibilité aux antibiotiques des bactéries isolées d'infections urinaires chez l'enfant au Maroc. *Revue Francophone des Laboratoires*. 2019;2019:65–70.
76. Zriouil SB, Bakkali M, Zerouali K. Epidemiology of *Staphylococcus aureus* infections and nasal carriage at the Ibn rochd university hospital center, casablanca, morocco. *Brazilian Journal of Infectious Diseases*. 2012;16.
77. Truppa C, Abo-Shehadeh MN. Antimicrobial resistance among GLASS pathogens in conflict and non-conflict affected settings in the Middle East: a systematic review. *BMC Infectious Diseases*. 2020;20.
78. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, et al. Antimicrobial resistance in Africa: A systematic review. *BMC Infectious Diseases*. 2017;17.
79. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, et al. Morbidity and mortality due to shigella and enterotoxigenic *Escherichia coli* diarrhoea: the Global Burden of Disease Study 1990–2016. *The Lancet Infectious Diseases*. 2018;18.
80. Luttring JD. Carbapenem-resistant Enterobacteriaceae: An emerging bacterial threat. *Seminars in Diagnostic Pathology*. 2019;36.
81. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. *BMJ*. 2016. <https://doi.org/10.1136/bmj.h6420>.
82. Suzuki S, Horinouchi T, Furusawa C. Prediction of antibiotic resistance by gene expression profiles. *Nature Communications*. 2014;5.
83. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. *Clinical Microbiology Reviews*. 2018;31.
84. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. *The Lancet Infectious Diseases*. 2017;17.
85. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network. *Antimicrobial Agents and Chemotherapy*. 2017;62.
86. Reed TAN, Krang S, Miliya T, Townell N, Letchford J, Bun S, et al. Antimicrobial resistance in Cambodia: a review. *International Journal of Infectious Diseases*. 2019;85:98–107.
87. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A Systematic Review and Meta-analysis of the Prevalence of Community-Onset Bloodstream Infections among Hospitalized Patients in Africa and Asia. *Antimicrobial Agents and Chemotherapy*. 2019;64.

88. O'Neal L, Alvarez D, Mendizábal-Cabrera R, Ramay BM, Graham J. Community-Acquired Antimicrobial Resistant Enterobacteriaceae in Central America: A One Health Systematic Review. *International Journal of Environmental Research and Public Health*. 2020;17.
89. Agyeman AA, Bergen PJ, Rao GG, Nation RL, Landersdorfer CB. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant *Klebsiella pneumoniae* infections. *International Journal of Antimicrobial Agents*. 2020;55.
90. Bilal H, Khan MN, Rehman T, Hameed MF, Yang X. Antibiotic resistance in Pakistan: a systematic review of past decade. *BMC Infectious Diseases*. 2021;21.
91. Rhouma M, Beaudry F, Letellier A. Resistance to colistin: what is the fate for this antibiotic in pig production? *International Journal of Antimicrobial Agents*. 2016;48.
92. Amajoud N, Bouchrif B, el Maoudi M, Skalli Senhaji N, Karraouan B, el Harsal A, et al. Prevalence, serotype distribution, and antimicrobial resistance of *Salmonella* isolated from food products in Morocco. *The Journal of Infection in Developing Countries*. 2017;11.
93. el Allaoui A, Rhazi Filali F, Ameer N, Bouchrif B. Contamination des élevages de dinde de chair par *Salmonella* spp. au Maroc: prévalence, antibiorésistances et facteurs de risque associés. *Revue Scientifique et Technique de l'OIE*. 2017;36.
94. Shigemura K, Fujisawa M. History and Epidemiology of Antibiotic Susceptibilities of *Neisseria gonorrhoeae*. *Current Drug Targets*. 2015;16.
95. Allan-Blitz L-T, Wang X, Klausner JD. Wild-Type Gyrase A Genotype of *Neisseria gonorrhoeae* Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis. *Sexually Transmitted Diseases*. 2017;44.
96. Karim S, Bouchikhi C, Banani A, el Fatemi H, Souho T, Erraghy S, et al. Molecular Antimicrobial Resistance of *Neisseria gonorrhoeae* in a Moroccan Area. *Infectious Diseases in Obstetrics and Gynecology*. 2018;2018.
97. Moghnieh RA, Kanafani ZA, Tabaja HZ, Sharara SL, Awad LS, Kanj SS. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. *The Lancet Infectious Diseases*. 2018;18:e379–94.
98. WHO. Global Antimicrobial Resistance Surveillance System Manual for Early Implementation. 2015.
99. European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2018. Stockholm; 2019.
100. Chen C-J, Huang Y-C. New epidemiology of *Staphylococcus aureus* infection in Asia. *Clinical Microbiology and Infection*. 2014;20.
101. Wangai FK, Masika MM, Maritim MC, Seaton RA. Methicillin-resistant *Staphylococcus aureus* (MRSA) in East Africa: red alert or red herring? *BMC Infectious Diseases*. 2019;19.
102. Lee AS, de Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, Peschel A, et al. Methicillin-resistant *Staphylococcus aureus*. *Nature Reviews Disease Primers*. 2018;4.
103. Cherazard R, Epstein M, Doan T-L, Salim T, Bharti S, Smith MA. Antimicrobial Resistant *Streptococcus pneumoniae*: Prevalence, Mechanisms, and Clinical Implications. *American Journal of Therapeutics*. 2017;24.
104. Feldman C, Anderson R. Recent advances in the epidemiology and prevention of *Streptococcus pneumoniae* infections. *F1000Research*. 2020;9.
105. Cornick JE, Bentley SD. *Streptococcus pneumoniae*: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. *Microbes and Infection*. 2012;14.
106. Schroeder MR, Stephens DS. Macrolide Resistance in *Streptococcus pneumoniae*. *Frontiers in Cellular and Infection Microbiology*. 2016;6.
107. Bouihat N, Burucoa C, Benkirane A, Seddik H, Sentissi S, al Bouzidi A, et al. *Helicobacter pylori* Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study. *Microbial Drug Resistance*. 2017;23:727–32.
108. Bouihat N, Burucoa C, Benkirane A, el Idrissi-Lamghari A, al Bouzidi A, el Feydi A, et al. High-level primary clarithromycin resistance of *Helicobacter pylori* in Morocco: A prospective multicenter molecular study. *Helicobacter*. 2015;20:422–3.
109. Rosenthal VD, Bat-Erdene I, Gupta D, Belkebir S, Rajhans P, Zand F, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2012-2017: Device-associated module. *American Journal of Infection Control*. 2020;48.
110. Elmouaden C, Laglaoui A, Ennane L, Bakkali M, Abid M. Virulence genes and antibiotic resistance of *Pseudomonas aeruginosa* isolated from patients in the Northwestern of Morocco. *The Journal of Infection in Developing Countries*. 2019;13.
111. Tsalik EL, Petzold E, Kreiswirth BN, Bonomo RA, Banerjee R, Lautenbach E, et al. Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. *Clinical Infectious Diseases*. 2017;64 suppl_1.

Tables

Table 1 Characterization of included studies

Study	Study design	Time enrolled	Moroccan location	Isolate source and sample	Susceptibility method used	GLASS Organism(s) included
[39]	Prospective	2008 - 2009	Primary health care in Marrakech	660 nasopharyngeal samples (children under 2 years)	E-test	<i>S. pneumoniae</i>
[70]	Prospective	2008	Ibn Sina UH, Rabat	Nasal carriage of 54 hemodialyzed patients	DDM	<i>S. aureus</i>
[58]	Retrospective	Mar 2006 - Jun 2010	Military Hospital Mohammed V, Rabat	307 samples corresponding to isolate bacterial strains from burn patients	DDM	<i>K. pneumoniae, E. coli</i>
[37]	Survey	1998 - 2008	Ibn Rochd UH of Casablanca	955 consecutive non-duplicate isolates recovered at the microbiology laboratory	DDM	<i>S. pneumoniae</i>
[66]	Prospective	Jan 2010 - Jan 2010	Private laboratory and Mohammed V Hospital Meknes	Urine samples from 480 inpatients and outpatients	DDM	<i>E. coli, Klebsiella.sp</i>
[52]	Surveillance	Sep 2007 - Aug 2008	Ibn Rochd UH of Casablanca	185 children aged ≤ 5 years diagnosed with bacterial invasive infection	ADM & DDM	<i>S. Pneumoniae</i>
[32]	Prospective	July 2009 - Dec 2010	UH Mohamed VI of Marrakesh	376 urine cytobacteriology (hospitalized infants)	DDM	<i>E. coli, K. pneumoniae</i>
[76]	Prospective	Jan - Jul 2007	Ibn Rochd UH of Casablanca	160 isolates from pathological samples of patients (79 cases) and nasal swabs (81) of cases and controls	DDM	<i>S. aureus</i>
[33]	Prospective	Jan 2010 - Dec 2011	Casablanca, El Jadida, Settat, Rabat, Meknes, Fez	1174 community acquired uropathogenic <i>E. coli</i> isolates	DDM	<i>E. Coli</i>
[61]	Prospective	Jan - Dec 2010	Ibn Sina University Hospital, Rabat	47 nonduplicate <i>A. baumannii</i> isolated from in-patients	DDM	<i>A. baumannii</i>
[60]	Prospective	Jan - Sep 2009	Military Hospital Mohammed V, Rabat	Non-redundant isolates of <i>P. aeruginosa</i> and <i>A. baumannii</i> from various samples	DDM	<i>A. baumannii</i>
[65]	Prospective	2010	UH Mohammed VI, Marrakech	38 cases of peritonitis (peritoneal fluid)	DDM	<i>E. coli, K. pneumoniae Streptococcus spp.</i>
[50]	Retrospective	Jul - Dec 2009	Five cities situated in north, central, west and south Morocco	171 men complaining of urethral discharge	E-Test	<i>N. gonorrhoeae</i>
[73]	Retrospective	May 2007 - May 2009	UH Mohammed VI, Marrakech and several health centers	Nasopharyngeal samples taken from healthy children aged 1-24 months (660 children)	DDM	<i>S. pneumoniae</i>
[42]	Cross-sectional	Jan to Jun 2012	Hemodialysis centers in Fez region	Nasal swab specimens (143 hemodialyzed outpatients and 32 medical staff)	DDM	<i>S.aureus</i>
[47]	Retrospective	Mar to Jun 2012	Clinical laboratories in Tangier-Tetouan region	111 Enterobacteriaceae isolates were collected with patient information	ADM	<i>Enterobacteriaceae</i>
[56]	Prospective	Jan 2011 - Jan 2012	CHU Ibn Sina Rabat	50 <i>A. baumannii</i> isolates from patients in intensive care unit	E-Test	<i>A. baumannii</i>
[57]	Prospective	Feb 2012 - Mar 2013	CHU Ibn Sina Rabat	Ear swabs were collected from patients at the pediatric hospital	DDM	<i>E. coli, K. pneumoniae, Streptococcus spp.</i>
[53]	Prospective	Nov 2008 - Feb 2009	Private hemodialysis centres in Casablanca	Nasal swabs (145 patients and 42 personnel)	DDM	<i>S. aureus</i>
[34]	Prospective	Jun - Aug 2011	Ibn Rochd UH of Casablanca	166 isolates recovered from urine (n=80), pus (n=34), blood (n=24), sputum (n=11) and others (n=17).	DDM	<i>K. pneumoniae</i>

[28]	Retrospective	Apr 2012 - July 2013	Military Hospital Mohammed V, Rabat	Isolates from inpatients and outpatients. Urine isolates represented 82%.	DDM	<i>E. coli</i>
[67]	Prospective	Jan 2012 - Dec 2013	UH Mohamed VI of Marrakesh	406 enterobacteriaceae strains isolated (urinary samples of hospitalized children)	DDM	<i>E. coli, Klebsiella.sp</i>
[54]	Retrospective	Nov 2010 - Dec 2012	Mohammed V Hospital Meknes	150 patients infected by <i>E. coli</i> from hematology (68.7%), urology (22%) and burn (16%) wards.	DDM	<i>E. coli</i>
[45]	Retrospective	Jan 2010 - Dec 2012	Avicenne Teaching Hospital, Marrakech	<i>K. pneumoniae</i> strains (urine samples)	BMD	<i>K. pneumoniae</i>
[46]	Retrospective	2010 - 2012	Avicenne Teaching Hospital, Marrakech	Uropathogenic <i>E. coli</i> (urine samples from in and outpatients)	BMD	<i>E. coli</i>
[41]	Prospective	2007 - 2014	Ibn Rochd University Hospital Casablanca	655 <i>S. pneumoniae</i> isolates (pediatric and adult patients)	DDM	<i>S. pneumoniae</i>
[40]	Retrospective	Jan 2012 - Dec 2013	Abderrahim El Harrouchi children hospital of Casablanca	34 patients (newborns)	ADM	<i>E. Coli, K. pneumoniae</i>
[38]	Not Mentioned	Mar 2001 - Mar 2012	Pediatric hospital of Rabat	Children under-5 with acute moderate-to-severe diarrhea	DDM	<i>Salmonella spp., E. coli, Shigella spp.</i>
[72]	Retrospective	2012-2014	Military Hospital Mohammed V, Rabat	clinical isolates of <i>Acinetobacter sp</i> (samples from inpatients)	DDM	<i>A. baumannii</i>
[63]	Prospective	Dec 2012 - Nov 2013	Military Hospital Mohammed V, Rabat	46 episodes of bacteremia recorded in 39 patients	DDM	<i>A. baumannii, K. pneumonia</i>
[30]	Prospective	Feb - July 2013	UH Hassan II, Fez	Hospitalized neonates (rectal swab specimens)	DDM	<i>E. coli, K. pneumonia</i>
[35]	Prospective	2012-2015	Laboratories of medical analysis from North-West of Morocco	516 clinical isolates. Specimens including urine (485), pus (15), vaginal specimen (10) and other ones with low rate.	DDM & BMD	<i>E. coli, Klebsiella spp.</i>
[51]	Prospective	2010-2014	Ibn Rochd University Hospital Casablanca	4232 non-duplicate blood cultures	DDM	<i>A. baumannii</i>
[43]	Prospective	2003-2009	Pasteur Ins., Casablanca	26 isolates from foodstuffs and humans samples	ADM	<i>Salmonella Infantis</i>
[59]	Retrospective	Apr 2007 - Dec 2015	Military Hospital Mohammed V, Rabat	451 wounds, 126 blood cultures and 50 catheter samples from burn inpatients	DDM	<i>E. coli, K. pneumoniae, Streptococcus spp.</i>
[29]	Prospective	Feb 2013 - July 2015	UH Hassan II, Fez	Intestinal carriage (newborns hospitalized in neonatal intensive care unit)	DDM	<i>A. baumannii</i>
[48]	Prospective	Apr 2015 - Jul 2016	MH, Regional hospital of Meknes and UH Center of Casablanca	Specimens including urine, pus, distal bronchial Levy protected, bronchial aspirate, central catheter, blood cultures and others.	ADM	<i>A. baumannii</i>
[75]	Retrospective	Jan 2013 - Dec 2017	UH Mohamed VI of Marrakesh	4 769 cytobacteriological examinations of urine (hospitalized children 0-17 years)	DDM	<i>E. Coli</i>
[44]	Prospective	Jun 2017 - Jun 2018	UH Mohamed VI of Marrakesh	Nasal carriage of <i>S. aureus</i> in 300 children consulting at different pediatric specialties	ADM & DDM	<i>S. aureus</i>
[49]	Retrospective	Jun 2015 - Jun 2016	Mohammed V Hospital Meknes	126 burn patients (86 infected)	DDM	<i>E. Coli</i>
[55]	Case control	Mar	UH Mohamed VI of	479 patients from the clinical and surgical ICU	DDM	<i>A. baumannii</i>

		2015 - Mar 2016	Marrakesh	enrolled with a first clinical episode of HAI.		
[71]	Survey	2015 - 2018	UH Ibn Rochd, Casablanca	19 <i>S. pneumoniae</i> isolates (community patients with respiratory tract infections)	BMD	<i>S. pneumoniae</i>
[68]	Case report	2017	UH Ibn Rochd, Casablanca	35-year-old female patient. Swab sample from the surgical wound.	DDM	<i>S. pneumoniae</i>
[31]	Prospective	Feb 2013 - July 2015	UH Hassan II, Fez	Intestinal carriage (newborns hospitalized in neonatal intensive care unit)	DDM	<i>E. coli</i> , <i>K. pneumoniae</i>
[62]	Retrospective	Jan 2016 - Jun 2019	Cheikh Khalifa International UH, Casablanca	Isolates of ESBL-EC isolated from 670 urine samples	DDM	<i>E. coli</i>
[69]	Prospective	Jan 2017 - Dec 2018	Medical analysis laboratories in Casablanca city	2090 urines samples collected throughout Casablanca from the health facilities	DDM	<i>E. coli</i>
[74]	Retrospective	Jun 2016 - Dec 2018	UH Mohammed VI of Oujda	863 positive blood cultures in the microbiology laboratory (adults, children and newborns)	Not indicated	<i>A. baumannii</i>
[36]	Retrospective	Jan 2012 - Dec 2018	Military Hospital Mohammed V, Rabat	10324 isolates of <i>E. coli</i>	DDM	<i>E. coli</i>
[64]	Case control	Jan - Dec 2018	UH Mohammed VI of Marrakesh	131 non-duplicate carbapenem-resistant Enterobacteriaceae	DDM	<i>E. coli</i> , <i>K. pneumoniae</i>

UH, University hospital; ADM, agar dilution method; DDM, disk diffusion method; BMD, broth microdilution

Table 2 Resistance rates for *E. coli* isolates.

Study	Nb of isolate	AMX-C n(%)	AMX n(%)	CRO n(%)	CTX n(%)	CAZ n(%)	Carb. n(%)	Fluorq. n(%)	SXT n(%)	GN n(%)	AK n(%)
[58]	7	5(71.4)	-	-	0(0.0)	-	0(0.0)	0(0.0)	2(28.6)	-	0(0)
[32]	133	92(69.0)	-	-	7(5.3)	-	0(0.0)	16(12.0)	70(52.5)	12(9.0)	3(2)
[66]	844	528(62.5)	-	-	-	148(17.5)	59(7.0)	253(30.0)	506(60.0)	224(26.5)	72(
[65]	15	10(64.0)	-	14(93.0)¥	-	-	15(100.0)	-	-	15(100.0)	15(
[33]	49	49(100.0)	49(100.0)	-	49(100.0)	49(100.0)	5(10.2)	40(81.6)	38(77.6)	31(63.3)	10(
[47]	69	40(58.0)	45(65.2)	30(43.5)	24(34.8)	22(31.9)	0(0.0)	26(37.7)	-	9(13.0)	0(0)
[57]	3	1(33.3)	3(100.0)	2(66.6)	-	-	-	2(66.6)	-	0(0.0)	-
[28]	*	532/1263 (42.1)	-	60/1032 (5.8)	-	-	31/1251 (2.5)	259/1020 (28.9)	456/1244 (36.7)	129/1137 (11.3)	18/ (1.4
[46]	924	436(47.1)	624(67.5)	-	-	-	0(0.0)	243(26.4)	522(56.5)	164(17.8)	106
[67]	224	148(66.0)	184(82.0)	47(21.0)¥	-	-	0(0.0)	27(12.0)	105(47.0)	38(17.0)	2(1
[54] †	690	296(48.6)	480(78.8)	-	69(11.3)	83(13.6)	0(0.0)	259(42.5)	141(23.2)	159(26.1)	14(
[54] ‡	150	130(86.7)	143(95.3)	-	53(35.3)	45(30.0)	0(0.0)	114(76.0)	141(94.0)	26(17.3)	14(
[38]	71	36(50.7)	-	-	2(2.8)	4(5.6)	1(1.4)	2(2.8)	40(56.3)	11(15.5)	2(2
[30]	67	58(86.6)	61(91.0)	-	56(83.6)	56(83.6)	-	44(65.7)	13(19.4)	57(85.1)	6(9
[35]	398	257(64.6)	-	-	96(24.1)	126(31.7)	23(5.8)	104(26.1)	-	85(21.4)	10(
[75]	Not available	-	(80.0)	-	(34.0)	-	(2.0)	(15.4)	(56.0)	(16.0)	(2.7
[49]	11	11(100.0)	10(90.9)	4(36.4)	2(18.2)	2(18.2)	2(18.2)	8(72.7)	7(63.6)	4(36.4)	2(1
[55]	25	-	-	-	-	-	10(41.0)	20(81.0)	20(81.0)	18(71.0)	4(1
[31]	152 on admission	65(42.8)	88(57.9)	-	56(36.8)	56(36.8)	18(11.8)	46(30.2)	38(25.0)	51(33.6)	2(3
[31]	109 during NICU stay	96(88.1)	100(91.7)	-	93(85.3)	93(85.3)	26(23.9)	77(70.6)	28(25.7)	89(81.7)	0(0
[62]	*	171(67)	252(100)	-	221(97.0)	233(93.0)	9(4.0)	235(94.0)	184(80.0)	109(44.0)	83(
[69]	230	88(38.2)	-	39(16.9)¥	-	-	-	62(27.0)	-	53(23.0)	16(
[36]	10 324	3717(36.0)	-	1239(12)¥	-	-	310(3.0)	3510(34.0)	4233(41.0)	1033(10.0)	310
[64]	13	-	-	-	-	-	13(100.0)	11(84.6)	10(76.9)	13(100.0)	-
Median (IQR)		64.0(47.1-71.4)	90.9(78.8-95.3)	28.7(15.7-49.3)	34.4(13.0-71.9)	31.8(18.0-84.0)	3.0(0.0-11.8)	34.0(26.3-71.7)	56.0(32.7-70.3)	23.0(15.8-53.7)	3.4(11.1

† *E. coli* isolated from community setting; ‡ *E. coli* isolated from hospital setting; * number of isolates varied by antibiotic tested; ¥ for 3GC.

3GC, Third-generation cephalosporins (CRO, CTX and CAZ); AMX-C, Amoxicillin-clavulanic acid; AMX, amoxicillin; CRO, Ceftriaxone; CTX, Cefotaxime; CAZ, Ceftazidime; Carb, Carbapenems; Fluorq, Fluoroquinolones; SXT, Trimethoprim-sulfamethoxazole; GM, Gentamicin; AK, Amikacin; NA, Nalidixic acid; Cs, Colistin; CFX, Cefoxitin.

Table 3 Resistance rates for *K. pneumonia* isolates

Study	Nb of isolate	AMX-C n(%)	AMX n(%)	CRO n(%)	CTX n(%)	CAZ n(%)	Cs n(%)	Carb. n(%)	Fluorq. n(%)	SXT n(%)	GN n(%)
[58]	18	7(39.3)	-	-	7(39.0)	-	-	1(5.5)	5(28.0)	8(44.4)	-
[32]	32	(42.0)	(100.0)	-	-	-	-	0(0.0)	(14.0)	(46.0)	(21.0)
[66]	384	243(63.0)	-	92(24.0)	-	148(39.0)	-	4(1.0)	142(37.0)	196(51.0)	133(35.0)
[65]	5	3(60.0)	-	-	-	5(100.0)*	-	5(100.0)	-	-	5(100.0)
[34]	166	91(54.8)	-	-	67(40.4)	67(40.4)	-	11(6.6)	61(36.8)	86(51.8)	64(38.6)
[47]	28	20(71.4)	-	16(57.1)	14(50.0)	13(46.4)	-	5(17.9)	12(42.9)	-	12(42.9)
[57]	3	2(66.6)	2(66.6)	3(100.0)	-	-	-	-	3(100.0)	-	2(66.3)
[45]	321	321(100.0) (51)¥	-	-	-	-	-	23(7.0) (0.0)¥	72(84.0) (32.0)¥	286(89.0) (61.0)¥	286(89.0) (21.0)¥
[67]	122	72(59.0)	122(100.0)	62(51.0)**	-	-	-	4(3.0)	31(25.0)	57(47.0)	55(45.0)
[40]	20	-	-	-	20(100.0)	-	-	(72.0)† (40.0)‡	-	-	-
[63]	10	6(60.0)	-	6(60.0)	-	6(60.0)	0(0.0)	2(20.0)	7(70.0)	8(80.0)	5(50.0)
[30]	83	75(90.4)	83(100.0)	-	72(86.7)	72(86.7)	-	-	39(47.0)	28(33.7)	72(86.7)
[35]	118	72(61.0)	-	-	43(36.4)	48(40.7)	27(22.9)	13(11.0)	30(25.4)	-	36(30.5)
[49]	18	18(100.0)	18(100.0)	15(83.3)	15(83.3)	15(83.3)	2(11.1)	9(50.0)	14(77.8)	15(83.3)	5(27.8)
[31]	124 on admission	80(64.5)	124(100.0)	-	79(63.7)	79(63.7)	-	17(13.7)	39(31.5)	49(39.5)	72(58.1)
[31]	195 during NICU stay	184(94.4)	195(100.0)	-	184(94.4)	184(94.4)	-	18(9.2)	90(46.2)	99(50.8)	169(86.7)
[64]	77	-	-	-	-	-	21(27.3)	76(98.7)	65(84.4)	68(88.3)	77(100.0)
Median (IQR)		63.0(59.5-80.9)	100.0	58.6(52.5-77.5)	63.7(40.4-86.7)	61.9(42.1-85.9)	17.0(8.3-24.0)	12.4(6.7-35.0)	42.9(29.8-73.9)	50.9(45.6-80.8)	50.0(36.8-86.7)

* 100% for C3G ; ** for 3CG ; † Imipenem ; ‡ Ertapenem ; ¥ % for Non-ESBL producing *K. pneumoniae* strains

AMX-C, Amoxicillin-clavulanic acid; AMX, amoxicillin; CRO, Ceftriaxone; CTX, Cefotaxime; CIP, Ciprofloxacin; CAZ, Ceftazidime; Cs, Colistin; Carb, Carbapenems; Fluorq, Fluoroquinolones ; SXT, Trimethoprim-sulfamethoxazole; GM, Gentamicin; AK, Amikacin; NA, Nalidixic acid

Table 4 Resistance rates for *A. baumannii* isolates.

Study	[58]	[60]	[61]	[56]	[72]	[51]	[63]	[59]	[29]	[48]	[49]	[55]
Nb of isolates	51	48	47	50	441	221	13	90	84	81	20	85
Tetracycline	-	-	-	-	400(90.9)	141(64.0)	-	-	-	-	-	-
AMX-C	-	-	-	-	-	-	-	-	-	-	20(100.0)	-
Ticarcillin	46(90.2)	-	47(100.0)	-	393(89.0)	-	13(100.0)	83(92.6)	66(78.6)	75(92.6)	20(100.0)	-
Piperacillin	-	-	47(100.0)	-	386(87.6)	-	13(100.0)	83(92.6)	68(81.0)	75(92.6)	20(100.0)	-
Piperacillin/ tazobactam	-	-	47(100.0)	-	349(79.2)	212(96.0)	13(100.0)	83(92.6)	22(26.2)	70(86.4)	20(100.0)	-
Ticarcillin/ clavulanic acid	-	-	47(100.0)	-	385(87.4)	-	-	-	65(77.4)	74(91.4)	20(100.0)	-
Ceftazidime	42(82.4)	-	46(98.0)	-	379(86.0)	188(85.0)	13(100.0)	83(92.6)	67(79.8)	75(92.6)	13(65.0)	-
Ceftriaxone	-	-	-	-	-	-	-	-	-	72(88.9)	-	-
Imipenem	35(68.6)	34(71.0)	27(57.4)	37(74.0)	336(76.2)	168(76.0)	13(100.0)	85(94.4)	9(10.7)	23(28.4)	18(90.0)	NR
Amikacin	36(70.6)	-	28(59.5)	-	231(52.3)	146(66.0)	(50.0)	48(53.0)	8(9.5)	41(50.6)	9(45.0)	63
Gentamycin	-	-	47(100.0)	-	-	172(78.0)	11(83.3)	85(94.4)	67(79.8)	60(74.1)	18(90.0)	80
Tobramycin	-	-	47(100.0)	-	190(43.0)	97(44.0)	7(53.8)	0(0.0)	67(79.8)	61(75.3)	20(100.0)	79
CIP	-	-	47(100.0)	-	387(87.8)	194(88.0)	13(100.0)	48(53.0)	64(76.2)	64(79.0)	20(100.0)	80
Levofloxacin	-	-	-	-	-	-	-	-	-	-	20(100.0)	-
Rifampicin	-	-	-	43(86.0)	142(32.1)	-	6(46.1)	48(53.0)	-	-	19(95.0)	-
Colistin	-	-	0(0.0)	0(0.0)	7(1.7)	2(1.0)	0(0.0)	0(0.0)	-	-	4(20.0)	0(0.0)
SXT	-	-	25(53.0)	-	348(79.0)	170(77.0)	12(92.3)	48(53.0)	8(9.5)	-	20(100.0)	41
Cefepime	-	-	46(98.0)	-	380(86.2)	-	-	-	-	72(88.9)	-	-
Netilmicin	-	-	-	-	146(33.1)	31(14.0)	6(46.1)	0(0.0)	-	-	-	-

ABRI, *Acinetobacter baumannii* resistant to imipenem; NR, not recommended; AMX-C, Amoxicillin-clavulanic acid; CIP, Ciprofloxacin; SXT, Trimethoprim-sulfamethoxazole

Table 5 Resistance rates for *S. pneumonia* isolates

Study	[39]	[37]	[52]	[73]	[57]	[41]	[71]	Median (IQR)
<i>Nb of isolates</i>	150	313 †	24	150	27	92 ‡	19 ¥	
Penicillin G	52(34.7)	-	2(8.3)*	58(38.7)	27(100.0)	75(81.5)	2(10.5)	36.7(10.0-86.1)
Amoxicillin	5(3.3)	3(1.0)	1(4.2)	17(11.3)	27(100.0)	-	2(10.5)	7.4(2.7-33.5)
AMX-C	-	-	-	-	27(100.0)	-	2(10.5)	-
Cefotaxime	0(0.0)	-	-	11(7.3)	-	-	-	-
Ceftriaxone	-	3(1.0)	0(0.0)	-	10(37.0)	-	2(10.5)	5.8(0.3-30.4)
Tetracycline	-	95(30.5)	-	75(50)	-	77(83.7)	-	50.0(30.5-83.7)
Erythromycin	-	45(14.4)	4(16.6)	93(62)	-	92(100.0)	4(21.0)	21.0(15.5-81.0)
Gentamycin	-	-	-	2(1.3)	21(77.8)	-	-	-
Ciprofloxacin	-	-	-	106(70.7)	7(25.9))	-	-	-
Levofloxacin	-	-	-	-	5(18.5)	-	2(10.5)	-
Chloramphenicol	-	25(8.1)	0(0.0)	57(38)	-	-	-	8.1(0.0-38.0)
SXT	-	74(23.8)	8(33.3)	96(57.3)	-	32(34.8)	3(15.8)	33.3(19.8-46.1)

† Survey of 2006-2008; ‡ Erythromycin-resistant *S. pneumonia*; ¥ EUCAST susceptibility; * For MIC $\geq$ 2mg/L

AMX-C, Amoxicillin-clavulanic acid; SXT, Trimethoprim-sulfamethoxazol

Figures

Figure 1

Flow diagram of the search results and selection of the included studies

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Appendices.docx](#)